Gleiter, Christoph H.

[["dc.bibliographiccitation.firstpage","17"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Fortschritte der Neurologie · Psychiatrie"],["dc.bibliographiccitation.lastpage","24"],["dc.bibliographiccitation.volume","68"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Junghanns, K."],["dc.contributor.author","Thiel, A."],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T11:05:30Z"],["dc.date.available","2018-11-07T11:05:30Z"],["dc.date.issued","2000"],["dc.description.abstract","During the last decade several new agents have been introduced in the treatment of depressive disorders. In comparison to classical tricyclic antidepressants, these agents have less side effects and a very low toxicity. Selective inhibitors of serotonin reuptake do not produce sedation; however, in the initial phase of treatment this is not always an advantage. In contrast, receptor antagonists, such as mirtazapin and nefazodone have moderate sleep-inducing properties. Selective agents are also characterized by certain pharmacologic interactions which can lead to considerable inhibition of the metabolism of other drugs. Classical antidepressants still play an important role in the treatment of severe depressive episodes. Different synaptic effects of new antidepressants lead to an increased availability of monoaminergic neurotransmitters. The article summarizes the most important neurobiological consequences of these acute synaptic effects which might be more closely associated with neurobiological correlates of depression. The authors conclude about the advantages and disadvantages of the different classes of antidepressants from a clinical point of view."],["dc.identifier.doi","10.1055/s-2000-11639"],["dc.identifier.isi","000085143600003"],["dc.identifier.pmid","10705571"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52080"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1439-3522"],["dc.relation.issn","0720-4299"],["dc.title","Advances in the pharmacotherapy of depression by new antidepressants"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","234"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Psychopharmacology"],["dc.bibliographiccitation.lastpage","241"],["dc.bibliographiccitation.volume","155"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Meyer, T."],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Hillmer-Vogel, U."],["dc.contributor.author","George, A."],["dc.contributor.author","Bartmann, U."],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T09:08:51Z"],["dc.date.available","2018-11-07T09:08:51Z"],["dc.date.issued","2001"],["dc.description.abstract","Rationale: Several clinical studies suggest antidepressive and anxiolytic effects of regular aerobic exercise. Objectives: The present study examines the effects of a 10-week protocol of moderate aerobic exercise (3-4 miles jogging 3 times per week) on central serotonergic receptor sensitivity. Methods: Neuroendocrine challenges using oral doses of meta-chlorophenylpiperazine (m-CPP; 0.4 mg/kg), ipsapirone (0.3 mg/kg), and placebo were performed in 12 untrained healthy volunteers before and after 10 weeks of moderate aerobic exercise. Results: Before training, administration of the non-selective serotonergic agonist m-CPP, which exerts a number of well-reproducible effects mainly via its action on 5-HT2C receptors, was associated with a significant increase of cortisol and prolactin (but not adrenaline or noradrenaline) in comparison with the placebo condition. After the 10-week training period, administration of m-CPP was followed by a blunted cortisol response which was not significantly increased in comparison to the placebo challenge, In contrast, the increases of cortisol observed after administration of the 5-HT1A agonist ipsapirone were of the same magnitude during the pre- and post-training challenge sessions. The behavioral response to ipsapirone and the mean maximal increases of plasma adrenaline and noradrenaline did not change during the training period. Conclusions: Regular aerobic exercise is associated with a blunted cortisol response to m-CPP, which might reflect a downregulation of central 5-HT2C receptors."],["dc.identifier.doi","10.1007/s002130100706"],["dc.identifier.isi","000169275000003"],["dc.identifier.pmid","11432685"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26124"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0033-3158"],["dc.title","Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Clinical Psychopharmacology"],["dc.bibliographiccitation.lastpage","161"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","George, A."],["dc.contributor.author","Jestrabeck, C."],["dc.contributor.author","Opitz, M."],["dc.contributor.author","Bartmann, U."],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Roed, I. S."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Hajak, Goran"],["dc.date.accessioned","2018-11-07T10:53:42Z"],["dc.date.available","2018-11-07T10:53:42Z"],["dc.date.issued","2000"],["dc.description.abstract","In patients with panic disorder and/or agoraphobia (PDA) an increased sensitivity of central 5-HT2C receptors and a decreased responsiveness of 5-HT1A receptors has been postulated. In the present study, neuroendocrine challenges were performed using oral doses of the non-selective 5-HT2C agonist m-chlorophenylpiperazine (m-CPP) (0.4mg/kg), the selective 5-HT1A antagonist ipsapirone (0.3mg/kg), and placebo in 40 patients with PDA and 12 healthy controls in order to compare 5-HT2C and 5-HT1A-specific psychobehavioural and neuroendocrine response patterns. At baseline, all psychobehavioural variables and the plasma concentration of noradrenaline (NE) were significantly increased in the patient group compared to the controls. The administration of m-CPP or ipsapirone was followed by comparable psychological symptoms and, in 55% of all patients, panic attacks. In comparison to the control subjects, patients were characterized by significantly higher psychological reactions to both challenge agents and a significantly higher NE response to m-CPP. In the patient group, there was also a trend towards an increased cortisol response after administration of m-CPP and a decreased cortisol and hypothermia response after administration of ipsapirone compared to the control group. The neuroendocrine findings of our study support earlier reports of opposite changes in the responsiveness of 5-HT2C- and 5-HT1A-related receptors in PDA patients. The behavioural hypersensitivity to both, m-CPP and ipsapiron, shows that the provocation of anxiety and other psychological symptoms might be influenced by cognitive factors. (C) 2000 Zippincott Williams & Wilkins."],["dc.identifier.doi","10.1097/00004850-200015030-00004"],["dc.identifier.isi","000086955900004"],["dc.identifier.pmid","10870873"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49403"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0268-1315"],["dc.title","Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]